4 completed, 1 active not recruiting, 1 recruiting. 4 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Active not recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Five Eleven Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers [18F]P17-059 - Parkinson Disease | Phase 1 | Completed | Five Eleven Pharma, Inc. | 4 | 2022-07-15 | 2023-01-11 |
| PSMA-PET to Guide Prostatectomy PSMA-PET and SOC MRI, SOC MRI - Prostate Cancer | Phase 2 / Phase 3 | Recruiting | Five Eleven Pharma, Inc. | 288 | 2021-10-01 | 2025-01-31 |
| Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Ga-68 P16-093 PET/CT scan - Prostate Cancer Recurrent, Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | Five Eleven Pharma, Inc. | 60 | 2018-05-10 | 2022-05-02 |
| Initial Investigation of [18F]P16-129 in Alzheimer's Disease Patients and Healthy Volunteers [18F]P16-129 - Alzheimer Disease | Phase 1 | Completed | Five Eleven Pharma, Inc. | 14 | 2018-02-21 | 2021-07-20 |
| Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer [68Ga]P16-093 - Prostate Cancer, Renal Cancer | Phase 1 | Completed | Five Eleven Pharma, Inc. | 30 | 2017-07-21 | 2025-02-26 |
| Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041 [68Ga]P15-041 - Prostate Cancer, Bone Metastases | Early Phase 1 | Completed | Five Eleven Pharma, Inc. | 14 | 2016-09-20 | 2023-01-12 |
Prostatic Neoplasms (4) · Alzheimer Disease (1) · Kidney Neoplasms (1) · Parkinson Disease (1)
(18 F)D3FSP (1) · 68 Ga-P16-093 (1)
United States (6)
Clinton Bahler, MD (1) · Mark Green, PhD (1) · Martin Pomper, MD PhD (1)